Pre-Made Taplitumomab Paptox biosimilar, Fusion Protein, Taplitumomab-Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody s for drug discovery and mechanism of action (MOA) research

Pre-Made Taplitumomab Paptox biosimilar, Fusion Protein, Taplitumomab-Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody s is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Taplitumomab paptox is a mouse monoclonal antibody. The antibody itself, taplitumomab, is linked to the protein PAP, an antiviral from Phytolacca americana, a species of pokeweed.[1] This is reflected by the 'paptox' in the drug's name.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1008-1mg	1mg	3090
GMP-Bios-INN-1008-10mg	10mg	Inquiry
GMP-Bios-INN-1008-100mg	100mg	Inquiry
GMP-Bios-INN-1008-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Taplitumomab Paptox biosimilar, Fusion Protein, Taplitumomab-Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody s
INN Name	Taplitumomab Paptox
Target	CD19
Format	Fusion Protein
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	0
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0